Introduction Executive Summary Cerebral Infarction: Overview ● Causes ● Mechanism of Action ● Signs and Symptoms ● Diagnosis ● Disease Management Pipeline Therapeutics ● Comparative Analysis Therapeutic Assessment ● Assessment by Product Type ● Assessment by Stage and Product Type ● Assessment by Route of Administration ● Assessment by Stage and Route of Administration ● Assessment by Molecule Type ● Assessment by Stage and Molecule Type Cerebral Infarction – DelveInsight’s Analytical Perspective In-depth Commercial Assessment ● Cerebral Infarction companies’ collaborations, Licensing, Acquisition -Deal Value Trends Cerebral Infarction Collaboration Deals ● Company-Company Collaborations (Licensing / Partnering) Analysis ● Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) ● Comparative Analysis PMZ-1620: Pharamzz ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) ● Comparative Analysis SP-8203: Shin Poong Pharmaceutical Co. Ltd. ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I/II) ● Comparative Analysis JTR-161: Teijin Pharma Limited ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Inactive Products ● Comparative Analysis Cerebral Infarction Key Companies Cerebral Infarction Key Products Cerebral Infarction- Unmet Needs Cerebral Infarction- Market Drivers and Barriers Cerebral Infarction- Future Perspectives and Conclusion Cerebral Infarction Analyst Views Cerebral Infarction Key Companies Appendix

Table 1 Total Products for Cerebral Infarction Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Genervon Biopharmaceuticals, LLC • Pharmazz • SanBio, Inc. • Bayer • Tasly Biopharmaceuticals Co., Ltd. • AstraZeneca • Athersys, Inc • NoNO Inc. • Materia Medica Holding • Dexa Medica Group • Shin Poong Pharmaceutical Co. Ltd. • Techfields Inc •Teijin Pharma Limited • NC medical research • Acticor Biotech • Meridigen Biotech Co., Ltd. • Prolong Pharmaceuticals